A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC) | MicrobiomeTrials← Back to trialsNCT05851924
A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2023-05-12Est. Completion: 2027-05
Enrollment target: 60 participants Locations- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
- Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack, New York, United States
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
Other microbiome trials you might be interested in
Malignant Solid TumorsOther Neoplasms Solid TumorsPediatric Solid TumorRefractory Solid TumorsSolid Tumor
Background:
Approximately 150 cases of cancer per one million per year are considered rare cancers. While all tumors or…
Bethesda, United StatesEst. completion May 31, 2028
Locally Advanced or Metastatic Solid Tumours
The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care che…
La Jolla, United StatesEst. completion Oct 7, 2024
Pancreatic CancerPancreatic Cancer MetastaticPDACPDAC - Pancreatic Ductal AdenocarcinomaPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma MetastaticPancreatic AdenocarcinomaPancreatic Adenosquamous Carcinoma
The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combinatio…
Tampa, United StatesEst. completion Dec 30, 2028